Patient Portal

Stephen T. Oh, MD, PhD

Assistant Professor, Medicine
Division of Hematology

Specialty Areas

Hematology
Hematologic Malignancies
Leukemia

Board Certifications

Internal Medicine
Hematology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia, chronic myelomonocytic leukemia, systemic mastocytosis, hypereosinophilic syndrome

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine

4921 Parkview Place
St. Louis, MO 63110

Suite: A
Floor: 7
Office Phone: 314-362-7216
Fax: 314-362-8813

Education

Education

A.B. (Biochemical Sciences) : Harvard University, Cambridge, MA 1996
Medical Degree: Cancer Biology, Medical Scientist Training Program, Northwestern University Feinberg School of Medicine, Chicago, IL 2004
Residency: Stanford University School of Medicine, Stanford, CA 2006
Fellowship: Hematology/Oncology, Stanford University School of Medicine, Stanford, CA 2010

Publication & Research

Publication & Research

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST
Blood Cancer J. 2015 Oct 2;5:e351

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R.
J Clin Oncol. 2015 Aug 31. pii: JCO.2015.61.6474. [Epub ahead of print]

Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, Wilson RK, Ley TJ, Oh ST 
Leukemia. 2015 Apr;29(4):869-76.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA.
J Natl Compr Canc Netw. 2015 Apr;13(4):424-34.

Prognostication in MF: From CBC to Cytogenetics to Molecular Markers.
Zhou A, Oh ST
Best Pract Res Clin Haematol. 2014 Jun;27(2):155-164.

Disseminated tuberculosis associated with ruxolitinib
Hopman RK, Lawrence SJ, Oh ST
Leukemia 2014 Aug;28(8):1750-1

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW
N Engl J Med 2013 May 9;368(19):1781-90

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM
Cancer Res 2013 Jan 1;73(1):285-296

Pathology consultation on myeloproliferative neoplasms
Schmidt AE, Oh ST
Am J Clin Pathol 2012 Jul;138(1):12-19

A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia
Zhang B, Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J
Blood 2011 Dec 22;118(26):6988-90

When the brakes are lost: LNK dysfunction in mice, men, and myeloproliferative neoplasms
Oh ST
Therapeutic Advances in Hematology 2011;2:11-19

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A
Leukemia 2010 Oct;24(10):1713-8

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J
Blood 2010 Aug 12;116(6):988-92

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Oh ST, Gotlib J
Expert Rev Hematol 2010 Jun;3(3):323-37

Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory
Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL
J Mol Diagn 2010 Jan;12(1):58-64

Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh ST, Gotlib J
Curr Hematol Malig Rep 2008 Jan;3(1):10-8

Areas of Research Interest

Myeloproliferative neoplasms, including the application of single cell mass cytometry to interrogate operturbed signaling networks in MPNs, and the application of next generation sequencing technologies to delineate genomic complexity and clonal evolution in MPNs.